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CHAPTER I
INTRODUCTION
Nicotine
Tobacco products are widely used by humans and the health problems associated
with cigarette smoking and other forms o f tobacco use are staggering (Julien, 1995).
Although the reasons for human tobacco use were debated for many years, it is now clear
that the underlying mechanism involves the positively reinforcing effects o f nicotine.
Humans (e.g., Henningfield & Goldberg, 1983), nonhuman primates (e.g., Goldberg,
Spealman, & Goldberg, 1981), and rats (e.g., Shoaib & Stolerman, 1999) will all selfadminister nicotine, and it is generally acknowledged that tobacco use in its various
forms provides a means o f self-administering the drug (Julien, 1995).
Despite the fact that nicotine can serve as a positive reinforcer, the drug is a
poisonous alkaloid, and was one o f the first known pesticides (Yamamoto, 1998). In the
tobacco plant the highest concentration o f nicotine is in leaves, where one small bite can
result in death for an insect. Extracts from the tobacco leaf have long been recognized as
effective insecticides that protected crops from leaf-eating insects (Crosby, 1966;
Schmeltz, 1971). As early as 1690 European farmers documented using a plant spray
made from tobacco extract to protect other kinds o f plants; roughly 250 years later
nicotine was commercialized as an insecticide in America (Schmeltz, 1971). Over the
years nicotine’s popularity as an insecticide decreased with the rise o f synthetic

1
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insecticides that were cheaper and more readily available (Yamamoto, 1998). Today, it
has no commercial application as an insecticide (Yamamoto, 1998).
The neurochemical effects of nicotine are well established and involve the
capacity of the drug to stimulate a class o f cholinergic receptors termed "nicotinic." At
low doses this stimulation results in: a slight increase in blood pressure and heart rate; a
heightened sense o f alertness, awareness and arousal; improved concentration, learning
and short-term memory; and decreased anxiety and pain perception (e.g., Benowitz et al.
1989; Clarke, 1993; Girod et. al., 1999). At higher doses, when the receptors are
stimulated too strongly, nicotine is a potent nerve poison that can cause headaches,
giddiness, nausea, vomiting, impaired vision and hearing, mental confusion, rapid
respiration, faintness, tremors, respiratory paralysis, convulsions and death (Schmeltz,
1971). The toxic effects of a large nicotine dose are noticed almost immediately and
nicotine, for which the median lethal intravenous dose in humans is estimated to be 30-60
mg/kg, can cause death in 5 - 30 minutes (Schmeltz, 1971). This dose range is never
approached by tobacco users and the harm associated with tobacco use primarily involves
chronic effects on the pulmonary and circulatory systems, not acute toxicity.
In recent years, researchers have explored the use of nicotine as a possible
treatment for several diseases. Levin (1992) reported that acute and chronic nicotine
administration can enhance cognitive function in both humans and animals. Since then,
studies have suggested that nicotine may help alleviate the cognitive impairments
associated with aging, Alzheimer’s disease, schizophrenia, attention-deficit/hyperactivity
disorder, and Tourette’s syndrome (e.g., Rezvani & Levin, 2001; Sanberg et al., 1997;
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White & Levin, 2004). Despite these promising findings, nicotine is not yet recognized
as an effective medication for any o f these conditions.
Behavioral pharmacologists have examined nicotine as a positive reinforcer (e.g.,
Clark, 1969; Hanson et al., 1979; Stolerman, 1991) and as a discriminative stimulus (e.g.,
Chance et al., 1978; Craft & Howard, 1988; Rosecrans & Villanueva, 1991; Schechter &
Rosecrans, 1972; Shoaib et. al., 1997; Stolerman, 1989). They also have examined its
direct effects on schedule-controlled responding. The effects o f nicotine on schedulecontrolled responding are complex and difficult to summarize, although acute injections
of moderate to high doses o f nicotine frequently produce dose-dependent decreases in
response rates under a variety o f schedules (e.g., Clarke & Kumar 1983; Goldberg et al.,
1989; Ksir, 1994; Morrison & Armitage, 1967). Low doses sometimes increase response
rates, and there is some evidence that the effects o f nicotine are rate- as well as dosedependent (e.g., Morrison, 1967; Morrison & Armitage, 1967; Pradhan, 1970; Spealman
et al., 1981; Stitzer et al. 1970).
Morrison (1967), for example, administered nicotine to rats responding under a
variable-ratio (VR) 30 schedule o f water reinforcement, and found that there was a slight
increase in responding at 0.05, 0.1, and 0.2 mg/kg, and a slight decrease in responding at
0.4 mg.kg. Similar results were reported by Spealman et al. (1981), who studied the
effects o f nicotine in squirrel monkeys responding under a multiple fixed-interval (FI)
300-s fixed-ratio (FR) 30 schedule o f food reinforcement. During the FI component, the
lowest nicotine dose (0.01 mg/kg) had no effect on behavior, whereas intermediate doses
(0.03, 0.1 and 0.3 mg/kg) increased responding, and the highest dose (1.0 mg/kg)
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decreased responding. In the FR component, nicotine produced a dose-dependant
decrease in responding. In addition to demonstrating how dose can influence the effects
of nicotine on schedule-controlled responding, the Spealman et al. (1981) study also
shows that the schedule under which behavior is maintained may influence nicotine's
actions.
The schedule o f reinforcement in effect is a powerful determinant o f response
rate, and response rate is known to modulate the effects o f many drugs (e.g., Dews &
Wenger, 1977; McKeamey & Barrett, 1978). Ratio schedules, for example, typically
produce high rates o f behavior whereas interval schedules typically produce lower rates
of behavior (Ferster & Skinner, 1957). In schedules that produce low baseline rates (e.g.,
long FI schedules), low nicotine doses often increase response rates (e.g., Morrison,
1967; Morrison & Armitage, 1967; Morrison & Stephenson, 1973; Pradhan, 1970;
Spealman et al., 1981; Stitzer et al., 1970). These same doses may decrease high baseline
response rates. Such an effect is illustrated in the Spealman et al. (1981) study described
above, wherein a dose o f nicotine that increased responding during the FI component
decreased responding in the FR component. In contrast to these results, however,
Morrison reported that nicotine increased the relatively high rates maintained under a VR
schedule.
In addition, although VI schedules typically engender higher response rates than
FI schedules o f the same length, several studies have revealed similar effects o f acute
nicotine administrations (0.05 - 0.4 mg/kg) under VI 2-min and FI 2-min schedules,
regardless of whether they were arranged singly or as components o f a multiple schedule
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(e.g., Morrison, 1967; Morrison & Armitage, 1967; Morrison & Stephenson, 1973;
Pradhan, 1970). In these studies, nicotine increased response rates under both FI and VI
schedules.
Goldberg et al. (1989) also reported that nicotine at doses o f 0.01 - 0.03 mg/kg
increased responding under the FI component o f a multiple FI 5-min FR 20 schedule of
food delivery, whereas 1.0 mg/kg reduced responding. However, Stitzer et al. (1970)
reported that nicotine (0.05 - 0.4 mg/kg) produced dose-dependent decreases in the
response rates o f rats performing under an FI 88-s schedule o f water reinforcement. The
inconsistency o f results observed under FI schedules suggests that the effects o f nicotine
on schedule-controlled responding may be influenced by a number o f variables, even
when overall response rates are relatively low.
As noted previously, under schedules that engender high response rates, low
nicotine doses typically have no effect or slightly increase response rates, while higher
doses decrease response rates in dose-dependent fashion (e.g., Goldberg et al., 1989;
Morrison, 1967; Morrison & Armitage, 1967; Pradhan, 1970). This pattern of results is
evident in experiments using FR 20 and 50 and VR 30 schedules, either alone or as
components o f a multiple schedule. Results showed that lower nicotine doses (0.05, 0.1,
and 0.2 mg/kg) produced a slight increase in response rates, while higher doses (0.4 and
1.0 mg/kg) produced a decrease in response rates (Goldberg et al., 1989; Morrison, 1967;
Morrison & Armitage, 1967). However, when examined under a multiple FR 20
Timeout (5 or 2.5 min) schedule of water reinforcement, nicotine at 0.2 mg/kg produced
a slight decrease in responding during the FR 20 component (Pradhan, 1970). When
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mice were trained to respond under an FR 25 schedule o f food reinforcement, nicotine
(0.2-1.6 mg/kg) produced a dose-dependent decrease in responding, with behavior almost
completely suppressed at the highest dose (Hendry & Rosecrans, 1982). Findings
obtained under ratio schedules, like those obtained under interval schedules, suggest that
the effects o f nicotine on schedule-controlled responding can be variable, although the
factors responsible for the variability are not readily apparent. One factor that may
influence results is the time when behavior is assessed relative to the time o f drug
injection. Some evidence suggests that nicotine may decrease responding relatively soon
after administration, then subsequently increase it (e.g., Clarke & Kumar 1983; Goldberg
et al., 1989; Ksir, 1994; Morrison & Armitage, 1967). If this is true, session length as
well as presession injection interval could influence the overall effects o f nicotine on
schedule-controlled responding, and both o f these variables vary substantially across
studies.
Because tobacco is used chronically, researchers have examined how the effects
of nicotine on schedule-controlled responding change with repeated exposures. In
principle, changes in drug effects with repeated exposures can involve either tolerance or
sensitization. Tolerance occurs when a given drug effect is reduced in magnitude as a
function of repeated exposure, whereas sensitization occurs when a given drug effect is
increased in magnitude as a function o f repeated exposure (Poling & Byrne, 2000).
Rightward and leftward shifts in the dose-response curve following repeated exposure
provide evidence o f tolerance and sensitization, respectively.
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Domino and Lutz (1973) found that tolerance developed to the rate-decreasing
effects o f nicotine when rats, trained to respond under an FR 15 schedule o f water
reinforcement, were given 0.25 mg/kg twice each day (pre- and post- session) for 15
days. Following an initial decrease in response rates, responding gradually increased
during repeated administration to baseline levels, indicating tolerance.
Hendry and Rosecrans (1982) trained mice to respond under an FR 25 schedule o f
food reinforcement. Initial nicotine administrations (0.2, 0.4, 0.8 and 1.6 mg/kg)
decreased responding in a dose-dependent manner. Next, the mice received daily
nicotine administrations (1.2 mg/kg) for 30 days. Response rates during repeated
nicotine administration showed an initial decrease, then gradually increased and returned
to baseline levels over the 30-day period. Additionally, the mice were again exposed to
the same doses (0.2, 0.4, 0.8 and 1.6 mg/kg) originally administered and the doseresponse curves for pre- and post- chronic administration were compared. Although the
post-chronic curve still showed dose-dependent rate decreases, the rates at a given dose
were much higher than when that dose was administered pre-chronically, indicating that
tolerance did develop.
Villanueva et al. (1992) replicated the work o f Hendry and Rosecrans (1982),
only they used rats responding under a VI 15-s schedule o f food reinforcement, with
initial nicotine administrations o f 0, 0.2, 0.4, and 0.8 mg/kg. Nicotine (0.8 mg/kg/day)
was then chronically administered for 36 days. The results that Villanueva et al. (1992)
reported were similar to those reported by Hendry and Rosecrans (1982), in that nicotine
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initially produced dose-dependent decreases in responding, and tolerance developed to
the rate-decreasing effects o f the drug.
Researchers initially believed that frequent (e.g., daily) administrations were
necessary for nicotine tolerance to develop. However, in recent years several studies
(e.g., Stolerman et al., 1974; Miller et al., 2001; MacPhail et al., 2000) have shown that
relatively infrequent administrations also result in tolerance. For example, Jarema et al.
(2002) extended to schedule-controlled behavior the research conducted by Miller et al
(2001), who demonstrated that tolerance developed to the locomotor effects o f nicotine
when the drug was given once a week. Jarema et al. used a multiple repeated acquisitionperformance schedule to determine whether tolerance to a single dose o f nicotine (0.6
mg/kg) would develop when that dose was administered weekly for 4 consecutive weeks.
Initial nicotine administrations decreased both response rate and response accuracy, but
tolerance developed rapidly to these effects. Similar effects were observed in both the
repeated acquisition and performance components. The results o f this pilot study are
interesting, and one purpose o f the present research was to examine further the effects of
widely-spaced nicotine administration on operant behavior in rats. The second purpose
was to compare the effects o f nicotine to those o f another drug with nicotinic cholinergic
actions, anatoxin-a.

Anatoxin-a
In addition to studying the effects o f nicotine, some researchers have examined
the effects o f other nicotine-like compounds, such as imidacloprid (Kagabu, 1997),
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indoxacarb (Zhao et al., 1999), nomicotine and cotinine (Goldberg et al., 1989), and to a
lesser extent those o f the cyanotoxin, anatoxin-a, which is a nicotine agonist (e.g.,
Stolerman et al., 1992; Stevens & Krieger, 1991; Carmichael & Falconer, 1993).
Anatoxin-a is an alkaloid neurotoxin produced by several genera o f cyanobacteria
(Falconer, 1993). Cyanobacteria, commonly referred to as blue-green algae because of
its color and similarity to algae, is typically found in warm, shallow, slow-moving or still
ffeshwaters, although it can also be found in sea water (Chorus & Bartram, 1999).
Warm, stagnant water rich in nutrients, such as lakes, ponds, roadside ditches, sewage
lagoons and agricultural runoffs set the stage for the rapid growth o f cyanobacteria often
called a "bloom" (e.g., Carmichael, 1994; Paerl et al., 2001; Villatte et al., 2002). These
blooms, also referred to as water or pond scum, often float on the water surface and are
most common in late summer and early fall when water temperatures are 72-80°F (2127°C) (Carmichael & Falconer, 1993). A cyanobacteria bloom may appear in as few as
two days and typically lasts 1-2 weeks, however, successive blooms may overlap and
appear as one continuous bloom (Crayton, 1993).
There are about 40 genera o f cyanobacteria and less than half o f them actually
produce toxins (Carmichael & Gorham, 1981; Falconer, 1993). Additionally, in some of
the toxin-producing genera the toxin levels are so low that they can be difficult to detect
(Carmichael & Gorham, 1981; Falconer, 1993). Cyanobacteria toxins, also called
cyanotoxins, are naturally produced poisons that are stored in the cells and typically not
released into the water until the cells rupture or die (Carmichael, 1994). However, the
most extreme poisonous effects are typically only experienced when the intact cell is
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ingested because the toxin becomes diluted when released into the water. These toxins
primarily attack the liver (hepatotoxins) and the nervous system (neurotoxins), or simply
irritate the skin (Chorus et al., 2000).
Most o f the time, cyanobacteria blooms have few harmful effects on plants or
animals. Nonetheless, when animals (including humans) drink or swim in water where
toxic blooms have formed, they sometimes experience cyanotoxin poisoning.
Cyanotoxins are responsible for illness or death in cattle, horses, sheep, pigs, birds, dogs,
rabbits, and small wild and domestic animals all over the world (e.g., Chorus et al., 2000;
Codd et al., 1997; Edwards et al., 1992). Cases o f cyanobacteria poisoning involving
humans typically stem from recreational exposure, often including ingesting water, and
result in mild discomfort such as skin and eye irritations, dizziness, fatigue, sore throat,
dry cough, and headache (e.g., Chorus & Bartrum, 1999; Codd, 1984). In rare cases
more serious symptoms such as, abdominal pain, nausea, vomiting, and diarrhea,
blistering o f the mouth, atypical pneumonia, and elevated liver enzymes in the serum
have been reported (Chorus & Bartram, 1999). These symptoms may be due to exposure
to the neurotoxin called anatoxin-a.
Anabaena, Aphanizomenon and Oscillatoria are three genera o f cyanobacteria
that produce the neurotoxin anatoxin-a (e.g., Carmichael, 1992; Duy et al., 2000).
Neurotoxins are typically rapid-acting poisons where signs can be observed minutes after
exposure and death may occur from 5 minutes to a few hours after exposure, depending
on dose. They affect the nervous system by interfering with nerve impulse transmission
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and can cause miosis, convulsions, tremor, seizures, and rigid paralysis (Patockaa &
Stredab, 2002).
(+)Anatoxin-a is a nicotinic agonist that binds to and stimulates neuronal nicotinic
acetylcholine receptors (e.g., Soliakov et al., 1995; Spivak et al, 1980). Exposure can
occur through ingestion, inhalation, injection, or through the skin at high concentrations
(e.g., Devlin et al, 1977; Patockaa & Stredab, 2002). The (+)anatoxin-a median lethal
dose for mice is 386 pg/kg i.v. Although the median lethal dose for humans is not
known, experts estimate it to be less than 5 mg, when ingested, for an adult male
(Patockaa & Stredab, 2002). Anatoxin-a was once referred to as Very Fast Death Factor
(VFDF) because signs can be observed within 5 minutes o f exposure and death can occur
within a few hours (e.g., Carmichael et al., 1979; Patockaa & Stredab, 2002). The
symptoms o f anatoxin-a poisoning follow a progression o f muscle twitching and spasms,
staggering, paralysis, convulsions, respiratory arrest, asphyxiation and lack o f oxygen to
the brain, and eventually death from suffocation (e.g., Carmichael, 1994; Carmichael &
Falconer, 1993; Patockaa & Stredab, 2002). Small laboratory animals (e.g., rats and
mice) typically exhibit gasping and sudden leaping movements before a sudden death,
while larger animals (e.g., dogs) often collapse and quickly die (Carmichael, 2001; Smith
& Lewis, 1987). There is no known treatment for anatoxin-a poisoning; however
respiratory support may allow time for the toxin to leave the body and recovery to occur
(e.g., Valentine et al., 1991; Codd et al, 1992).
To date there has only been one human case appearing to involve death from
anatoxin-a poisoning. A 2003 article by Don Behm, in the Milwaukee Journal Sentinel,
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stated that in July 2002 a healthy 17-year-old boy spent 15 minutes in a shallow golfcourse pond with a friend in Dane County, Wisconsin, and died two days later. Prior to
his death, the boy suffered from stomach cramps, vomiting, and uncontrollable diarrhea.
He then went into shock and suffered a seizure before his heart failed. High levels of
anatoxin-a were present in blood and tissue samples taken from this boy and his friend,
who also suffered severe diarrhea and abdominal pain. The final autopsy report lists the
likely cause o f death as ingestion of toxic algae, which led to "acute diarrhea illness and
subsequent death” (Behm, 2003).
Scientists have determined that anatoxin-a is a neurotoxin that primarily attacks
the respiratory system, potentially paralyzing the lungs and sending the heart into arrest
but they have not yet determined exactly how it kills (Campbell & Sargent, 2004). In
animal studies death typically occurs within two hours o f exposure to a toxic dose of
anatoxin-a, so it puzzling that the Wisconsin boy survived for so long after exposure. It
is perhaps for this reason that the cause o f death is not listed as anatoxin-a poisoning.
In the last several years, anatoxin-a has been found in waters throughout the
world. Many researchers are now studying this toxin for several reasons including
determining the human health risks. The anatoxins also are being studied for their
possible use as military weapons (Patockaa & Stredab, 2002), and, like nicotine,
cyanobacteria toxins are being studied as possible treatments for Alzheimer’s disease and
other disorders (Carmichael, 1994). The majority of research has examined where
anatoxin-a is found in nature, how it is formed, what it does in the brain, and its toxicity.
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Very little is known, however, about its behavioral effects, especially at less-than-lifethreatening doses.
Because o f its similarity to nicotine, scientists have recently begun to examine the
effects o f anatoxin-a under behavioral procedures that have previously been used with
nicotine. However, the literature is very limited. Stolerman, Albuquerque and Garcha
(1992) appear to be the only researchers who have published research on the behavioral
effects o f anatoxin-a and its similarity to nicotine.
Stolerman et al. (1992) reported the locomotor effects o f anatoxin-a in rats that
were not previously exposed to nicotine (non-tolerant) and in rats that had previously
received nicotine. Additionally, they reported the effects o f anatoxin-a in a salinenicotine drug discrimination procedure. They found that rats not previously made
tolerant to nicotine showed a decrease in activity with increasing anatoxin-a doses,
although there was a slight increase at the lowest dose, similar to the effects o f low doses
of nicotine.

The activity-decreasing effects o f anatoxin-a were substantially greater in

rats previously made tolerant to nicotine than in rats not exposed to nicotine. The drug
discrimination results indicated some similarities between anatoxin-a and nicotine, but
mecamylamine did not block the effects o f anatoxin-a. Mecamylamine typically blocks
the effects of nicotine in a drug discrimination procedure (e.g., Clarke & Kumar, 1983;
Reavill et al 1990).
The findings o f Stolerman et al (1992) suggest that anatoxin-a, like nicotine, can
have powerful behavioral effects. Even though this nicotinic agonist is similar to nicotine
in many ways, differences in their effects are apparent. Nothing has been reported
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concerning the effects o f anatoxin-a on schedule-controlled responding. Therefore, it is
of interest to compare its effects to those o f nicotine in subjects responding under
schedules of operant reinforcement. Moreover, nothing is known concerning the
development o f tolerance to anatoxin-a. The present study examined the pre- and post
chronic effects o f the compound on schedule-controlled responding o f rats.

Rationale for Studying Schedule-Controlled Behavior

Schedules o f operant reinforcement are critical to understanding the behavioral
effects o f drugs (Branch, 1991). Dews (1955) published a seminal article demonstrating
how the effects o f pentobarbital on pigeon’s key-peck responding depended on the
schedule of reinforcement that maintained that key pecking. He showed how the same
dose o f pentobarbital would increase responding under a fixed-ratio (FR) schedule and
decrease it under a fixed-interval (FI) schedule, illustrating that schedules of
reinforcement are fundamental determinants o f the behavioral effects o f drugs.
Subsequent studies have repeatedly confirmed that this is indeed true (e.g., Branch, 1991;
Poling & Byrne, 2000).
The schedule chosen for the present study was a multiple variable-ratio 30
variable-interval 60-s (mult VR 30 VI 60-s) schedule o f food reinforcement. Under a VI
schedule the intervals between reinforcement opportunities vary in random or nearly
random order (Ferster & Skinner, 1957). Therefore, under a VI 60-s schedule the
opportunity for reinforcement will be presented, on the average, every 60 seconds.
Because it is an interval schedule, one response is required after the time period has
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elapsed before reinforcement. This schedule typically produces moderate and relatively
constant response rates throughout the experimental session (Catania, 1992). Because of
this characteristic, VI schedules have long been used to investigate the behavioral effects
of drugs (Iverson & Lattal, 1991).
Under a VR schedule, reinforcement occurs after a given number o f responses
that vary unpredictably from one reinforcement to the next (Ferster & Skinner, 1957).
Under a VR 60 schedule, for example, reinforcement will be presented, on the average,
following every 60th response. In the absence o f drug, VR schedules typically engender
brief post-reinforcement (pre-ratio) pausing, followed by relatively high-rate responding
(Ferster & Skinner, 1957). Because rate o f reinforcement and rate o f responding are
directly related under VR schedules, drug-induced rate decreases o f the sort that acute
injections o f nicotine (and, by inference anatoxin-a) should inevitably lead to
reinforcement loss relative to control (no drug) conditions. So long as some minimal rate
of responding occurs, comparable rate decreases under VI schedules do not lead to
reinforcement loss. In 1966, Schuster, Dockens, and Woods (1966) developed the
reinforcement-loss hypothesis in an attempt to predict when tolerance would and would
not develop to a drug's effects on operant behavior. They proposed that:
Behavioral tolerance will develop in those aspects of the organism's behavioral
repertoire where the action of the drug is such that it disrupts the organism's
behavior in meeting the environmental requirements for reinforcement.
Conversely, where the actions o f the drug enhance, or do not affect, the
organism's behavior in meeting reinforcement requirements, we do not expect the
development o f behavioral tolerance, (p. 181).
The present study examined whether differential tolerance developed under a
multiple schedule with VR and VI components. A multiple schedule comprises two or
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more independent schedules that alternate throughout the session, with each schedule
correlated with a different stimulus (Catania, 1992). Multiple schedules are popular in
pharmacology research because they provide a way for researchers to collect data from
two different behavioral measures (schedules) in a single experiment. Two different
schedules were arranged in the present study to increase the amount o f information
generated regarding the drugs o f interest, and to ascertain whether the type o f schedule
arranged modulated tolerance to infrequent administrations o f nicotine and anatoxin-a.
Based on prior studies, we expected that both drugs would decrease responding under
both the VR 30 and VI 60-s schedules. Such an effect would necessarily reduce the
frequency of reinforcement under the VR schedule, but not under the VI. In many, but
not all, prior studies, and consistent with the reinforcement-loss hypothesis, tolerance
developed quicker or to a greater extent under schedules where the initial effect o f the
drug was reinforcement loss rather than reinforcement gain or no change in reinforcement
frequency (e.g., Comfield-Sumner & Stolerman, 1978).
The present experiments systematically compared the effects o f acute and
episodic exposures to nicotine and to anatoxin-a, a nicotine-like compound. Two
separate three-phase studies were conducted, one with nicotine and one with anatoxin-a.
The studies were equivalent, save for the drug administered. In the first phase, we
accomplished two objectives. First, we determined acute dose-effect relations. Second
we compared the changes that occurred with weekly dosing over a four- week period, and
determined whether tolerance developed. The second phase was similar to the first in that
weekly administrations were given over four consecutive weeks. However, in Phase II
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we wanted to determine not only if tolerance would develop, but also if it would be
sustained over a time period o f three weeks between injections. In the third Phase we
addressed the question o f whether behavioral or pharmacological tolerance developed to
the effects o f nicotine and anatoxin-a.
Experimenters studying repeated nicotine exposure have found that tolerance will
often develop to nicotine’s depressant effects and sensitization to its stimulant effects
(e.g., Clarke & Kumar, 1983; Miller et al., 2001; Reid et al., 1996; Walter &
Kuschinsky, 1989). Moreover, early research suggested that several weeks of
administration were necessary before tolerance to nicotine would develop (Mattila and
Saamivarra, 1967). Since the majority o f research on sensitization and tolerance to
nicotine involves locomotor activity as a measure of behavior, it will be only briefly
mentioned here. Instead, the main focus o f this paper is on the effects that chronic
nicotine and anatoxin-a exposure have on schedule-controlled responding.
Researchers studying the effects o f chronic nicotine administration, by measuring
locomotor activity as a measure o f behavior, have found that tolerance can develop with
daily (e.g., Stolerman et al., 1974), twice-weekly (e.g., Morrison & Stephenson, 1973)
and weekly (e.g., Miller et al., 2001) administrations, shown by an increase in activity
with subsequent nicotine administrations. With regard to schedule-controlled
responding, when nicotine is administered chronically, at doses that tend to initially
decrease responding, there is often an increase in responding following the subsequent
(repeated) administrations (e.g. Domino & Lutz, 1973; Hendry & Rosecrans, 1982;
Jarema et al., 2002; Villanueva et al., 1992).
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CHAPTER II
EXPERIMENT 1
Materials and Methods
Subjects
Eighty-eight experimentally-naive adult male Long-Evans rats (Charles River,
Raleigh, NC), approximately 90 days old at experiment inception, were maintained at
350g via daily food restriction (Purina Rat Chow, St. Louis, MO) and served as subjects.
Upon arrival the rats were given time to acclimate to the housing colony and
reach their target weight o f 350 g. They were fed ad libitum until they approached that
weight and then were switched to a weight-maintenance program where their daily food
allotment was gradually reduced and regulated so they maintained a weight o f 350 g (Ali
et al., 1992). The rats were on this weight-maintaining feeding schedule for the duration
o f the experiment.
The rats were housed individually in 19.5 x 45.5 x 25.0 cm hanging plastic cages,
with pine shaving bedding, in a temperature- (21-23°C) and humidity- (50-55%)
controlled colony. A lighting schedule o f 12-hr light and 12-hr dark was in effect (light
on at 6:00 am) with water available ad libitum. During the experiment proper, sessions
were conducted Monday through Friday during the light cycle. Rats were transported to
the laboratory for daily testing in individual plastic cages, with filter tops, measuring 15.5
x 27.5 x 15.0 cm.

18
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Apparatus
Behavioral sessions were conducted in commercially available operant test
chambers (Coulboum Instruments, Inc., Lehigh Valley, PA) positioned inside soundattenuating enclosures (Ralph Gerbands Co., Arlington, MA) and ventilated by a fan.
The inside o f the test chamber measured 30 cm wide x 24 cm deep and 31 cm tall. A grid
floor was raised 3.5 cm from the bottom o f the chamber to allow for a collection pan and
to keep the inside o f the chamber clean. The front and back sides o f the chamber were
made o f clear plastic while the right (component panel), left, top and bottom sides were
metal. The front side opened down to allow access into the chamber. Each chamber was
equipped with one response lever located on the right side o f the component panel, 5 cm
above the grid floor. Lever operation required a minimum downward force o f 0.25 N. A
set of triple-cue lights was located 3.5 cm directly above the lever. A pellet trough, into
which 45-mg food pellets (P.J. Noyes Co. Inc., Lancaster, NH) could be dispensed from a
dry-food feeder, was located to the left o f the lever and 1.5 cm above the grid floor. The
trough contained an overhead cue light that was briefly illuminated during food-pellet
delivery. A Sonalert tone generator was situated 16 cm above the lever and was activated
briefly (100 msec) after each response. A houselight, darkened only during food
delivery, was situated at the top center of the component panel. Experimental events and
data collection were controlled by a Digital Equipment Corporation (Maynard, MA) PDP
11/73 computer, programmed with the SKED-11 system (Snapper et al., 1982).
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Behavioral Procedure
Subjects were initially trained to lever press during one 8-hour overnight training
session. This session comprised three successive schedules. First, a variable-time 60-s
(VT 60-s) schedule was in effect for 60 food pellet presentations. Under this schedule,
food was delivered on average every 60 s, regardless o f the rat’s behavior. In addition,
conditions were arranged such that, if the lever was pressed 20 times, the schedule
immediately shifted to a fixed-ratio (FR) 1. Under this schedule, every response
produced a food pellet. If the lever was not pressed a minimum o f 20 times, the VT 60-s
schedule continued until 60 minutes had elapsed, at which time the schedule changed to
an FR 1. Upon completing 60 responses under the FR 1 schedule, the value was
increased to FR 2, which remained in effect until the rat emitted another 60 responses, at
which time the session ended. If all three schedule requirements were not met, the
session ended after eight hours had elapsed.
Handshaping and FR training were conducted during the days following the
overnight session for those rats that did not acquire the lever-press response. If they still
were not pressing the lever after two additional training days, food pellets were crushed
and placed on the lever. On a few occasions the rats also needed to be trained to eat
from the food cup. In this situation, the crushed food pellets were not only placed on the
lever but on the edge o f the food cup as well.
Upon completion o f the training procedure, each rat was exposed to a variableratio (VR) schedule o f food reinforcement during daily 23-min sessions. Rats were first
exposed to a VR 3, then to VR 5, VR 10, VR 20, and VR 30-response schedule o f
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reinforcement. The rate at which the ratios were increased was based on each rat’s
individual performance. Under the VR schedule, food was delivered following
completion o f a varying number o f responses, with the mean ratio requirement equal to
the specified schedule. Thus, on average, every 30th response produced food under the
VR 30 schedule.
When rate o f responding under the VR 30 schedule was stable (no visible trend)
for at least six days, the terminal schedule, a multiple VR 30 variable-interval (VI) 60-s
schedule (mult VR 30 VI 60-s), was introduced. Under this schedule the two
components, VR 30 and VI 60-s, alternated in 2-min blocks with sessions always starting
with the VR component. Under the VI 60-s schedule, food became available on average
once every 60-s, and was delivered dependent on a lever press. The triple-cue lights
served as a discriminative stimulus for the VR component while the house light was the
discriminative stimulus for VI responding. That is, the triple-cue lights were illuminated
only during VR 30 components and the house light was illuminated only during VI 60-s
components. During food delivery the feeder light was the only light illuminated as the
cue lights and house light were briefly darkened. No lights were illuminated during 5-s
blackout periods between components. Each daily session lasted 45-48 minutes and
ended after completion o f the final VI component.

Pharmacological Procedure
Subjects were exposed to the mult VR 30 VI 60-s schedule o f food reinforcement
until there were no visible trends in response rates across 10 consecutive sessions (i.e.,
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performance was stable). Thereafter, each subject received subcutaneous injections of
either isotonic saline or nicotine 5-min prior to testing. (-)-Nicotine hydrogen tartrate
(Sigma-Aldrich, St. Louis, MO) was dissolved in isotonic saline solution and prepared at
an injection volume o f 1 ml/kg. Doses are expressed as total salt weights. Subjects were
tested Monday through Friday with dosing on Wednesdays. Doses and pre-session
injection intervals were based on previous work by MacPhail et al. (2000) and Stolerman
et al. (1974).
Phase I
Rats were divided at random into 6 groups (n=8) and received weekly injections
of either saline or nicotine (0.125,0.3,0.6,1.2,1.8 mg/kg) for 4 weeks. An ED50 was
next derived (by linear interpolation) from the week 1VR response-rate (percent-ofcontrol) data and used during the second and third phases.
Phase II
Rats were divided at random into 4 groups (n=8) and received injections o f the
nicotine ED50 (0.73 mg/kg), derived from Phase I, once a week for four weeks. Group 1
(NNNN) received nicotine injections each week for four weeks (a replication o f the
pharmacological procedures in Phase 1). Group 2 (NVVN) received nicotine on the first
and fourth weeks only, with saline-vehicle injections during the middle two weeks.
Group 3 (VVVN) received vehicle injections for the first three weeks and nicotine during
the last week only. Group 4 (VVVV) received vehicle injections during all four weeks.
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Phase III

Eight rats were given weekly injections o f saline and the nicotine ED50 (0.73
mg/kg), derived from Phase I, for four weeks.

During the first three weeks each rat

received a saline injection before the session and nicotine after the session. During the
fourth week nicotine was given before the session and saline was not administered.

Results
Phase I
Figure 1 shows the dose-response data for variable-ratio response rates (VRrsp),
variable-ratio reinforcement rates (VRmf), variable-interval response rates (VIrsp) and
variable-interval reinforcement rates (VImf) when nicotine was administered on 4 weekly
occasions. Following the initial administration, nicotine produced dose-dependent
decreases in response rates and reinforcement rates in both components o f the multiple
schedule, although no nicotine dose completely suppressed behavior. Statistical analysis
by Repeated Measures Analysis o f Variance (ANOVA) showed a significant effect (for
all statistical tests, significance is defined at p < 0.05) o f drug dose on all four dependent
measures during the nicotine administration (Pr>F = 0.0001 for VRrsp, VRmf, V Im f and
Pr>F = 0.0002 for VIrsp). Post-hoc (Tukey) analyses revealed a statistically significant
difference between vehicle and the three highest doses (0.6, 1.2 and 1.8 mg/kg) for all
dependent variables. The two lowest doses (0.125 and 0.3 mg/kg) were not significantly
different from vehicle, with the exception o f VIrsp where 0.3 mg/kg nicotine differed
significantly vehicle.
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Subsequent nicotine administrations show a diminished effect indicating
substantial tolerance. Visual inspection o f the data in Figure 1 clearly illustrates the
reduced effect o f each nicotine dose across subsequent weekly administrations. The
biggest changes occurred from the first to the second administration.
Vehicle control values remained stable across all 4 weeks, demonstrating that
performance did not shift simply as a function o f the injections. Baseline values (data not
shown) also remained both stable and comparable to vehicle control values.
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Figure 1: VR and VI response and reinforcement rates following Phase I vehicle (saline)
or nicotine (mg/kg). Each symbol represents mean + SEM o f eight rats.
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Estimated ED50 values for each exposure to nicotine were calculated for each
dependent measure to quantify changes in drug effects with repeated exposure (Table 1).
Estimated ED5o values for all four dependent variables increased across exposures to
nicotine for response and reinforcement rates in the variable-ratio (VR) component,
indicating tolerance. In the variable-interval (VI) component, ED50 values steadily rose
across the first three exposure, indicating the progressive development o f tolerance.
There was, however, no increase from the third to the fourth exposure, indicating that the
greatest change in the ED50S occurred between the first two weeks with effects lessening
between the third and fourth weeks.
Table 1

Week 1
Week 2
Week 3
Week 4

VRrsp
0.73 mg/kg
1.97 mg/kg
2.55 mg/kg
3.36 mg/kg

Estimated ED50 Values for Nicotine
VRmf
VIrsp
0.20 mg/kg
0.72 mg/kg
1.96 mg/kg
4.49 mg/kg
2.44 mg/kg
7.06 mg/kg
3.28 mg/kg
6.60 mg/kg

V Im f
1.23 mg/kg
3.00 mg/kg
9.56 mg/kg
5.77 mg/kg

Pairwise comparisons were made using contrast statements calculated for each
between-week comparison, at every dose, for all four dependent measures (Tables 2-5).
Results revealed a statistically significant effect, expressed by the shaded areas, in the
first 3 weeks (between weeks 1&3 or weeks 2&3) for all doses in each dependent
measure, except 0.125 mg/kg in VImf, where the only significant contrast statement at
the lowest dose was between weeks 1 & 4.
VRrsp contrast statements (Table 2) indicated significant differences between
weeks 1 and 3 for 0.3, 0.6, 1.2, and 1.8 mg/kg (Pr>F = 0.0002, 0.0131, 0.0026 and
0.0002, respectively) and between weeks 2 and 3 for 0.125 mg/kg (Pr>F = 0.0128).
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Dose
0.125
0.3
0.6
1.2
1.8

Contrast
Weeks
1&2
0.8449
0.0213
0.0546
0.0053
0.0002

Table 2
Statements for Nicotine Phase I VRrsp
Weeks
Weeks
Weeks
Weeks
1&4
2&3
2&4
1&3
0.1933
0.13
0.0128
0.0768
0.0117
0.0002
0.0014
0.0165
0.0109
0.0001
0.0131
0.0031
0.1349
0.0851
0.0026
0.0085
0.0001
0.3286
0.0112
0.0002

Weeks
3&4
0.7418
0.0636
0.046
0.5605
0.0722

V R m f contrast statements (Table 3) indicated significant differences between
weeks 1 and 3 for 0.3, 0.6, 1.2, and 1.8 mg/kg (Pr>F = 0.0008, 0.0142, 0.0032 and
0.0001, respectively) and between weeks 2 and 3 for 0.125 mg/kg (Pr>F = 0.0112).

Table 3

Dose
0.125
0.3
0.6
1.2
1.8

Contrast Statements for Nicotine Phase I VRrnf
Weeks
Weeks
Weeks
Weeks
Weeks
1&2
1&4
2&3
2&4
1&3
0.0774
0.8053
0.1596
0.1166
0.0112
0.0019
0.0136
0.0094
0.0234
0.0008
0.0142
0.0576
0.0142
0.0003
0.0035
0.1302
0.173
0.0032
0.01
0.0073
0.39
0.0136
0.0003
0.0001
0.0001

Weeks
3&4
0.7504
0.0581
0.0391
0.5667
0.0786

VIrsp contrast statements (Table 4) indicated significant differences between
weeks 1 and 3 for 0.3, 0.6, 1.2, and 1.8 mg/kg (Pr>F = 0.0001, 0.0004, 0.0009 and
0.0001, respectively) and between weeks 2 and 3 for 0.125 mg/kg (Pr>F = 0.0066).

Table 4

Dose
0.125
0.3
0.6
1.2
1.8

Contrast Statements for Nicotine Phase I VIrsp
Weeks
Weeks
Weeks
Weeks
Weeks
2&4
1&2
1&3
1&4
2&3
0.0521
0.3619
0.0441
0.0403
0.0066
0.0003
0.0001
0.0011
0.0012
0.0061
0.0004
0.0002
0.0103
0.0295
0.0001
0.2902
0.0009
0.0451
0.0176
0.0046
0.0836
0.0001
0.0001
0.0001
0.0389

Weeks
3&4
0.3987
0.3352
0.0375
0.7927
0.3403
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V Im f contrast statements (Table 5) indicated significant differences between
weeks 1 and 3 for 0.3, 0.6, 1.2, and 1.8 mg/kg (Pr>F = 0.0047, 0.0019, 0.0011 and
0.0001, respectively) and between weeks 1 and 4 for 0.125 mg/kg (Pr>F = 0.0009).

Contrast Statements
Weeks
Weeks
Dose 1&2
1&3
0.8416
0.5247
0.125
0.0047
0.3
0.0056
0.0009
0.0019
0.6
1.2
0.0041
0.0011
0.0003
0.0001
1.8

Table 5
for Nicotine Phase I VIrnf
Weeks
Weeks
Weeks
1&4
2&3
2&4
0.1612
0.1468
0.0009
0.4052
0.2756
0.0055
0.0515
0.0009
0.0018
0.1337
0.0071
0.0045
0.0127
0.0001
0.0052

Weeks
3&4
0.4277
0.262
0.3086
0.9554
0.8742

In summary, detailed analysis o f the four data sets as a function o f the number o f
weekly exposures to nicotine confirms that tolerance developed to the effects o f the drag
on both response rate and reinforcement rate, and under both VI and VR schedules.
Phase II
Figure 2 shows VR and VI response rates and reinforcement rates during Phase II.
Vehicle (VVVV) controls, represented by the inverted triangles, remained stable across
all four weeks o f dosing. The only nicotine dose (0.73 mg/kg) used during phase II was a
derived ED50 value, based on the results from phase I. The group that was a replication
o f phase I (NNNN) represented by the circles in Figure 2, produced similar results as in
phase I. There was a decrease in response rates and reinforcement rates in both
components o f the multiple schedule following initial administration. Effects then
lessened across weekly nicotine administrations.
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Figure 2: VR and VI response and reinforcement rates following Phase II vehicle
(saline) and nicotine (0.73 mg/kg) injections. Each symbol represents mean
+ SEM o f eight rats.
Response and reinforcement rates for the group that received nicotine the first and
fourth weeks only (NVVN) are slightly higher during week 4 than during week one,
indicating that some tolerance developed. There is about a 25% increase in all dependent
variables (27% for VRrsp, 25% for VRmf, 26% for VIrsp and 28% for VImf) from
week 1 to week 4 in NVVN, indicating slight tolerance.
Looking at the first nicotine injection only, it appears that the three additional
weeks o f testing did not influence the effects o f nicotine on response and reinforcement
rates for the group that received nicotine during the last week only (V W N ). During
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week 4, when nicotine was first administered to the W V N group, the rates were not
significantly different from the groups (NNNN and N W N ) that first received nicotine
during week 1. When expressed as a percent o f the baseline control (data not shown),
NNNN (47% for VRrsp, 34% for VRmf, 50% for VIrsp and 53% for VImf) and NVVN
(47% for VRrsp, 46% for VRmf, 52% for VIrsp and 61% for VImf) during week 1 and
W V N (43% for VRrsp, 43% for VRmf, 49% for VIrsp and 69% for VImf) during week
4, all produced similar results.
Additionally, these percent of baseline control values add support to our derived
ED50 from phase I. The two groups that received nicotine during week 1 (NNNN and
NVVN) both show a 53% decrease from baseline responding following their first
nicotine injections, while the group that received nicotine for the first time during week 4
(V W N ) showed a 57% decrease. Even though these values are slightly higher than 50%
it still shows that our derived dose of 0.73 mg/kg was very close to an ED50. This
comparison is only made in the VRrsp component because that is the only dependent
measure used to calculate the derived ED50 from the Phase I data
Phase III
The third phase was included to determine whether tolerance was due to
behavioral or pharmacological variables. Vehicle injections were given before each
weekly test session and nicotine was given after each weekly test session during the first
3 weeks. In week 4, nicotine was administered for the first time before the weekly test
session. The only nicotine dose (0.73 mg/kg) used during phase II was the derived ED50
value based on the results from phase I.
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Figure 3: VR and VI response and reinforcement rates following Phase III vehicle
(saline) or nicotine (0.73 mg/kg) injections. Baseline values were determined
by averaging data from the day before injections for all rats. Each symbol
represents the mean + SEM o f eight rats.
Figure 3 shows VR and VI response rates and reinforcement rates following
Phase III saline and nicotine injections. Baseline values (day before each injection day)
are represented by the circles, and Phase III test data are represented by the inverted
triangles. During the first 3 weeks, when vehicle was given before the session, and
nicotine after the session, both response and reinforcement rates were very consistent,
indicating that vehicle injections did not affect performance. In week 4, when nicotine
was given before the session, there were small decreases (27% for VRrsp, 28% for
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VRmf, 13% for VIrsp and 39% for VImf) in response and reinforcement rates relative to
those obtained in week 3, when nicotine was not administered before the session.
These phase III results indicate that both pharmacological and behavioral
tolerance occurred. There was a change in rates from the first 3 weeks, when vehicle was
given before the session, to the 4th week, when nicotine was given before the session, so
we know that tolerance that developed was not purely pharmacological (i.e., due to drug
exposure per se). Moreover, this change was not statistically significant (Pr>F = 0.5754
for VRrsp, 0.5399 for VRmf, 0.9116 for VIrsp, and 0.0253 for V Im f) for most o f the
variables, so it is not solely behavioral tolerance. The only statistically significant result
was for V Im f (Pr>F = 0.0253) and post-hoc (contrast) statements revealed that the
significance was between weeks 2 and 4.

Discussion
Weekly administration of nicotine (0.125, 0.3, 0.6, 1.2 and 1.8 mg/kg) produced
behavioral tolerance over a period of four weeks during Phase I. Initial nicotine
administrations (Week 1) decreased response rates and reinforcement rates in generally a
dose-dependent manner in both the VR and VI components of the multiple schedule,
although no dose completely suppressed behavior. Each subsequent weekly nicotine
administration resulted in slightly higher response and reinforcement rates, indicating that
tolerance developed. These results are similar to previous findings under conditions

where nicotine was administered less frequently than once per day (Jarema et al., 2002;
MacPhail et al., 2000; Miller et al., 2001; Stolerman et al., 1974).
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During the second phase, when nicotine administrations with the derived ED50
dose (0.73mg/kg) were separated by a 3-week period, some tolerance also developed.
Results indicate about a 25% increase, from the first to the fourth week, in response rates
for both the VR and VI components, suggesting that tolerance will develop to nicotine
when the period between administrations is greater than one week. Although previous
studies have shown that tolerance can develope to nicotine when the drug is administered
once a week, the results o f Phase II appear to be the first demonstration o f tolerance when
the drug is administered less often than that. In addition, the group in Phase II that was a
replication of the conditions in Phase I produced similar results as in Phase 1, providing
additional support for the Phase I findings.
Phase III was included in this experiment as a way to examine whether the
tolerance was more behavioral or pharmacological in nature. Pharmacological tolerance
means the tolerance is the result o f exposure to a drug p er se, whereas behavioral
tolerance means that tolerance is the result o f performing the behavior o f interest in the
drug state. Behavioral tolerance is evident when a drug produces smaller effects
following chronic exposure in animals that have repeatedly performed the task o f interest
in the presence o f the drug than in other animals that have had comparable drug exposure,
but have not performed the task in the presence o f drug. Unfortunately, the data from
Phase III were not nearly as orderly as those for the first two phases and therefore are
difficult to interpret. They suggest, however, that some degree both behavioral and
pharmacological tolerance developed to the effects o f nicotine.
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In all, the present findings indicate that intermittent acute (episodic) nicotine
administrations can result in the development o f tolerance. Additional testing should
extend these findings by examining different reinforcement schedules and different time
periods between injections, and by determining the extent to which performing the task of
interest in the presence o f drug influences tolerance. Further research should also
determine whether tolerance develops to other nicotine-like compounds such as the
chloronicotinyl insecticide imidacloprid (Kagabu, 1997).
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CHAPTER III
EXPERIMENT 2
Materials and Methods
Subjects
One hundred and four experimentally naive adult male Long-Evans rats (Charles
River, Raleigh, NC), approximately 90 days old at experiment inception, were
maintained at 350 grams via daily food restriction (Purina Rat Chow, St. Louis, MO) and
served as subjects.
Upon arrival the rats were given time to acclimate to the housing colony and
reach their target weight o f 350 grams. They were fed ad libitum until they approached
that weight and then were switched to a weight-maintenance program where their daily
food allotment was gradually reduced and regulated so they maintained a weight o f 350
grams (Ali et al., 1992). The rats were on this weight-maintaining feeding schedule for
the duration o f the experiment.
The rats were housed individually in 19.5 x 45.5 x 25.0 cm hanging plastic cages,
with pine shaving bedding, in a temperature- (21-23°C) and humidity- (50-55%)
controlled colony. A lighting schedule o f 12-hr light and 12-hr dark was in effect (light
on at 6:00am) with water available ad libitum. During the experiment proper, sessions
were conducted M onday through Friday during the light cycle. Rats were transported to

34
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the laboratory for daily testing in individual plastic cages, with filter tops, measuring 15.5
x 27.5 x 15.0 cm.

Apparatus
Behavioral sessions were conducted in commercially available operant test
chambers (Coulboum Instruments, Inc., Lehigh Valley, PA) positioned inside soundattenuating enclosures (Ralph Gerbands Co., Arlington, MA) and ventilated by a fan.
The inside of the test chamber measured 30 cm wide x 24 cm deep and 31 cm tall. A grid
floor was raised 3.5 cm from the bottom o f the chamber to allow for a collection pan and
to keep the inside o f the chamber clean. The front and back sides o f the chamber were
made o f clear plastic while the right (component panel), left, top and bottom sides were
metal. The font side opened down to allow access into the chamber. Each chamber was
equipped with one response lever located on the right side of the component panel, 5 cm
above the grid floor. Lever operation required a minimum downward force o f 0.25 N. A
set of triple-cue lights was located 3.5 cm directly above the lever. A pellet trough, into
which 45-mg food pellets (P.J. Noyes Co. Inc., Lancaster, NH) could be dispensed from a
dry-food feeder, was located to the left o f the lever and 1.5 cm above the grid floor. The
trough contained an overhead cue light that was briefly illuminated during food-pellet
delivery. A Sonalert tone generator was situated 16 cm above the lever and was activated
briefly (100 msec) after each response. A houselight, darkened only during food
delivery, was situated at the top center o f the component panel. Experimental events and
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data collection were controlled by a Digital Equipment Corporation (Maynard, MA) PDP
11/73 computer, programmed with the SKED-11 system (Snapper et al., 1982).

Behavioral Procedures
Subjects were initially trained to lever press during one 8-hour overnight training
session. This session comprised three successive schedules. First, a variable-time 60-s
(VT 60-s) schedule was in effect for 60 food pellet presentations. Under this schedule,
food was delivered on average every 60 s, regardless o f the rat’s behavior. In addition,
conditions were arranged such that, if the lever was pressed 20 times, the schedule
immediately shifted to a fixed-ratio (FR) 1. Under this schedule, every response
produced a food pellet. If the lever was not pressed a minimum o f 20 times, the VT 60-s
schedule continued until 60 minutes had elapsed, at which time the schedule changed to
an FR 1. Upon completing 60 responses under the FR 1 schedule, the value was
increased to FR 2, which remained in effect until the rat emitted another 60 responses, at
which time the session ended. If all three schedule requirements were not met, the
session ended after eight hours had elapsed.
Handshaping and FR training were conducted during the days following the
overnight session for those rats that did not acquire the lever-press response. If they still
were not pressing the lever after two additional training days, food pellets were crushed
and placed on the lever. On a few occasions the rats also needed to be trained to eat
from the food cup. In this situation, the crushed food pellets were not only placed on the
lever but on the edge o f the food cup as well.
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Upon completion o f the training procedure, each rat was exposed to a variableratio (VR) schedule o f food reinforcement during daily 23-min sessions. Rats were first
exposed to a VR 3, then to VR 5, VR 10, VR 20 and VR 30-response schedule of
reinforcement. The rate at which the ratios were increased was based on each rat’s
individual performance. Under the VR schedule, food was delivered following
completion o f a varying number o f responses, with the mean ratio requirement equal to
tfi
the specified schedule. Thus, on average, every 30 response produced food under the
VR 30 schedule.
When rate o f responding under the VR 30 schedule was stable (no visible trends)
for at least six days, the terminal schedule, a multiple VR 30 variable-interval (VI) 60-s
schedule (mult VR 30 VI 60-s), was introduced. Under this schedule the two
components, VR 30 and VI 60-s, alternated in 2-min blocks with sessions always starting
with the VR component. Under the VI 60-s schedule, food became available on average
once every 60-s, and was delivered dependent on a lever press. The triple-cue lights
served as a discriminative stimulus for the VR component while the house light was the
discriminative stimulus for VI responding. That is, the triple-cue lights were illuminated
only during VR 30 components and the house light was illuminated only during VI 60-s
components. During food delivery the feeder light was the only light illuminated as the
cue lights and house light were briefly darkened. No lights were illuminated during 5-s
blackout periods between components. Each daily session lasted 45-48 minutes and
ended after completion o f the final VI component.
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Pharmacological Procedures
Subjects remained on the mult VR 30 VI 60-s schedule o f food reinforcement
until there were no visible trends in response rates across 10 consecutive sessions (i.e.,
performance was stable). Thereafter, each subject received subcutaneous injections of
either isotonic saline or anatoxin-a 5-min prior to testing. (+)-Anatoxin-a fumarate
(Sigma-Aldrich, St. Louis, MO) was dissolved in isotonic saline solution and prepared at
an injection volume o f 1 ml/kg. Doses are expressed as total salt weights. Subjects were
tested Monday through Friday with dosing on Wednesdays. Doses and pre-session
injection intervals were based on Stolerman et al. (1974) and pilot work in our laboratory.
Phase I
Rats were divided at random into 6 groups (n=8) and received weekly injections
of either saline or anatoxin-a (50, 100, 150, 200, 250 pg/kg) for 4 weeks. After the first
two injections we observed that 250 pg/kg completely suppressed behavior. Because 200
pg/kg nearly suppressed behavior when initially administered, we decided that no useful
information would be gained from additional injections o f the 250 pg/kg dose and
therefore it was discontinued. In addition, visual analysis o f the dose-response curve
indicated a substantial decrease in response rates from the 50 to the 100 pg/kg doses.
Therefore, we decided to test two additional doses (75 pg/kg and 125 pg/kg) wit two
additional groups o f rats (n=8). Each of these doses was given once a week for four
weeks as described above.
An ED50 was next derived (by linear interpolation) from the initial VR responserate (percent-of-control) data using 50, 75, 100, 150 and 200 pg/kg; this ED50 was used
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during the second and third phases o f the experiment. It is important to note that two
doses (125 pg/kg and 250 pg/kg) were not used in calculating the ED50. The higher dose
(250 pg/kg) was not included because it initially completely suppressed responding.
Moreover, visual inspection o f the effect o f the 125 pg/kg dose led us to conclude it was
an anomaly, although no cause for it was apparent. In any case, data obtained at this dose
were not used in calculating the ED50. Had those data been used, the ED50 would have
been 102 pg/kg, 10 pg/kg higher than the ED50 dose with those data excluded (92 pg/kg),
which was used in Phases II and III.
Phase II
Rats were divided into 4 groups (n=8) and received injections for 4 weeks. Group
AAAA received anatoxin-a injections each week for 4 weeks (a replication o f the
pharmacological procedures in phase I). Group AVVA received anatoxin-a on the first
and fourth weeks only, with saline-vehicle injections during the middle two weeks.
Group VVVA received vehicle injections for the first three weeks and anatoxin-a during
the last week only. Each o f these groups received 92 pg/kg anatoxin-a. Group 4 VVVV
received vehicle injections during all four weeks.
Phase III
Eight rats were given weekly injections of saline and the anatoxin-a ED50 (92
pg/kg), derived from Phase I, for four weeks.

During the first three weeks each rat

received a saline injection before the session and anatoxin-a after the session. During the
fourth week anatoxin-a was given before the session and saline was not administered.
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Results
Phase I
Figure 1 shows dose-response curves for variable-ratio response rates (VRrsp),
variable-ratio reinforcement rates (VRmf), variable-interval response rates (VIrsp) and
variable-interval reinforcement rates (VImf) when anatoxin-a was administered on 4
weekly occasions. Following the initial administration, anatoxin-a produced dosedependent decreases in response rates and reinforcement rates in both components o f the
multiple schedule. Although the two lowest anatoxin-a doses (50 and 75 pg/kg) only
produced slight decreases from baseline, the next highest dose (100 pg/kg) produced a
significant effect. The two highest doses (150 and 200 pg/kg) strongly reduced response
and reinforcement rates, and the slight differences between them are not statistically
significant for any dependent variable. Statistical analysis by Repeated Measures
Analysis o f Variance (ANOVA) showed a significant effect (for all statistical tests,
significance is defined at p < 0.05) for all four dependent measures during the first week
of anatoxin-a administration (Pr>F = 0.0001 for VRrsp, VRmf, VIrsp and VImf). Posthoc (Tukey) analyses revealed a statistically significant difference between vehicle and
the three highest doses (100,150 and 200 pg/kg), but not between vehicle and the lowest
doses (50 and 75 pg/kg), for all dependent measures.
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Figure 4: VR and VI response and reinforcement rates following Phase I vehicle (saline)
or anatoxin-a (pg/kg). Each symbol represents mean + SEM o f eight rats.
Subsequent anatoxin-a administrations show a diminished effect, indicating
substantial tolerance, for most o f the doses. Visual inspection o f the data in Figure 1
shows that for the most part the biggest change in effect occurred from the first to the
second exposure to the compound. Two anatoxin-a doses, 50 pg/kg and 200 pg/kg,
represented by the squares and circles, respectively, did not show a substantial change
across the four weeks o f testing. The highest dose (200 pg/kg) completely suppressed
behavior in the first 2 weeks with just a slight increase during weeks three and four.
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Additionally, 75 j_Lg/kg actually produced rates equal to or greater than baseline values in
both measures o f VI performance.
Vehicle control values remained stable across all 4 weeks, demonstrating that
performance did not shift simply as a function o f the injections. Baseline values (data not
shown) also remained both stable and comparable to vehicle control values.
Estimated ED5o values for each exposure to anatoxin-a were calculated for each
dependent measure to quantify changes in effects o f the compound with repeated
exposure (Table 6). Consistent with the graphic analysis, systematic changes in the
estimated ED5os are indicative o f tolerance. Table 6 shows an increase in the estimated
ED50 values for response and reinforcement rates in the VR and VI components across
the first three weekly anatoxin-a administrations, indicating tolerance. The rates did not
increase further between weeks 3 and 4; in fact, some decreases were apparent.
Table 6

W eekl
Week 2
Week 3
Week 4

VRrsp
91.94
118.56
147.02
134.54

Estimated ED5qValues
V R rn f
90.24 pg/kg
pg/kg
pg/kg
117.49 pg/kg
pg/kg
145.50 pg/kg
pg/kg
133.63 pg/kg

for Anatoxin-a
VIrsp
94.69 pg/kg
121.21 pg/kg
150.39 pg/kg
130.08 pg/kg

V Irn f
116.53
156.31
203.58
166.40

pg/kg
pg/kg
pg/kg
pg/kg

Pairwise comparisons were made using contrast statements calculated for each
between-week comparison, at every dose, for all four dependent measures (Tables 7-10).
Results revealed a statistically significant effect, expressed by the shaded areas, in the
first 3 weeks (1&3 or 2&3) for the three middle doses in each dependent measure, except
75 pg/kg in VIrsp where there were there was no statistically significant difference
between any o f the weeks. There was not a substantial change across the 4 weeks for the
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lowest (50 pg/kg) or highest (200 pg/kg) doses. However, there was a significant change
between the second and fourth weeks for the 200 jag/kg dose.
VRrsp contrast statements (Table 7) indicated significant differences between
weeks 1 and 3 for 75, 100 and 150 pg/kg (Pr>F = 0.0029, 0.0380 and 0.0262,
respectively).

Table 7
Contrast Statements for Anatoxin-a Phase I VRrsp
Weeks
Weeks
Weeks
Weeks
Weeks
2&4
Dose 1&2
1&3
1&4
2&3
0.6131
0.9467
0.7978
0.5798
0.3867
50
0.3872
0.3327
0.0512
0.0029
75
0.0295
0.1101
0.1109
0.0221
0.0706
100
0.038
0.0881
0.0224
0.0715
0.093
150
0.0161
0.6174
0.8222
0.2804
0.0651
0.6058
200

Weeks
3&4
0.5035
0.5993
0.6156
0.6133
0.9732

V R m f contrast statements (Table 8) indicated significant differences between
weeks 1 and 3 for 75, 100 and 150 pg/kg (Pr>F = 0.0037, 0.0364 and 0.0244,
respectively).

Table 8
Contrast Statements for Anatoxin-a Phase I VRrnf
Weeks
Weeks
Weeks
Weeks
Weeks
Dose 1&2
1&3
1&4
2&3
2&4
0.6168
0.9087
0.8202
0.6278
0.4126
50
0.3662
0.0037
0.0256
0.2765
75
0.0401
0.0364
0.022
0.0688
0.1298
100
0.1051
0.0244
0.0914
0.1051
0.0268
0.0777
150
0.5117
0.8401
0.7433
0.3259
0.0544
200

Weeks
3&4
0.4884
0.4912
0.05224
0.488
0.7093

VIrsp contrast statements (Table 9) indicated significant differences between
weeks 1 and 3 for 100 and 150 pg/kg (Pr>F = 0.0045 and 0.0272, respectively).
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Table 9
Contrast Statements for Anatoxin-a Phase I VIrsp
Weeks
Weeks
Weeks
Weeks
Weeks
1&3
1&4
2&3
2&4
Dose 1&2
0.6528
0.1704
0.1607
0.1597
0.9399
50
0.4142
0.3863
0.355
0.0719
0.1836
75
0.0622
0.2931
0.0045
100
0.0206
0.0138
0.068
0.104
0.0272
0.0315
0.0666
150
0.4392
0.7591
0.223
0.0979
0.658
200

Weeks
3&4
0.5501
0.9229
0.0569
0.4463
0.9501

V Im f contrast statements (Table 10) indicated significant differences between
weeks 1 and 3 for 100 and 150 pg/kg (Pr>F = 0.0090 and 0.0001, respectively), and
between weeks 2 and 3 for 75 pg/kg (Pr>F = 0.0475).

Table 10
Contrast Statements for Anatoxin-a Phase I VIrnf
Weeks
Weeks
Weeks
Weeks
Weeks
1&4
2&3
2&4
Dose 1&2
1&3
0.1947
0.6182
0.9266
0.1798
0.6571
50
0.0862
0.6062
0.945
0.7586
0.0475
75
0.1167
0.4159
0.0666
0.009
0.0143
100
0.0001
0.0596
0.0803
150
0.0219
• 0.0001
0.7604
0.2729
0.3527
0.2058
0.0257
200

Weeks
3&4
0.2027
0.5489
0.0274
0.2893
0.9353

In summary, detailed analysis o f the four data sets as a function o f the number o f
weekly exposures to anatoxin-a confirms that tolerance developed to the effects o f the
compound on both response rate and reinforcement rate, and under both VI and VR
schedules.
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Figure 5: VR and VI response and reinforcement rates following Phase II vehicle
(saline) and anatoxin-a (92 pg/kg) injections. Each symbol represents mean
+ SEM o f eight rats.

Phase II
The only anatoxin-a dose (92 pg/kg) used during phase II was a derived ED50
value, based on the results from phase I. The group that was a replication o f phase I
(AAAA), represented by the circles in figure 4, produced results that differed in some
regards from those o f phase I. There was a decrease in response rates and reinforcement
rates in both components o f the multiple schedule following initial administration, and
the effects then lessened between the first and second weekly administrations, as they did
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in Phase I. However, during the third weekly administration for AAAA, VR and VI
response and reinforcement rates sharply decreased to nearly 25% below those obtained
the week before. Group VVVV also showed a slight decrease in response and
reinforcement rates during the third week for all components except VIrsp. No known
equipment or experimenter error can account for this decrease. The effect o f anatoxin-a
on all rates increased again in week 4 but they were still slightly lower than in week 2.
Vehicle (VVVV) rates during week 4 were similar to those observed during the first two
weeks.
Response and reinforcement rates for the group that received anatoxin-a in the
first and fourth weeks only (A W A ) did not change significantly over the four weeks,
except for the unexplainable decrease during week 3, indicating that tolerance did not
develop. There is about a 5% increase (5% for VRrsp, 6% for VRmf, and 5% for VImf)
from weekl to week 4 in A W A , suggesting that no tolerance occurred. There was
actually a 3% decrease from week 1 to week 4 for VIrsp.
A comparison o f the first anatoxin-a administration (AAAA) and the vehicle
control (VVVV) show almost a fifty percent reduction (44%) for VRrsp, supporting our
derived ED50 value. This comparison is only made in the VRrsp component because it is
the only one used to calculate the derived ED50 from the Phase I data. Group A W A ,
which also received anatoxin-a during the first week, was not significantly different from
AAAA, and W V A was not statistically significant from VVVV during week 1.
Looking at the first anatoxin-a injections only, the rates were not significantly
different for groups AAAA and A W A , which first received anatoxin-a during week 1.
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When expressed a percent o f the baseline control (data not shown), results for AAAA
(68% for VRrsp, 68% for VRmf, 73% for VIrsp and 82% for VImf) are very similar to
those for A W A (68% for VRrsp, 69% for VRmf, 71% for VIrsp and 90% for VImf)
during week 1 administration. However, for the group (W V A ) that first received the
anatoxin-a during week 4, the percent o f the baseline control values (90% for VRrsp,
89% for VRmf, 101% for VIrsp and 95% for VImf) are much higher than those observed
in the two groups (AAAA and A W A ) that first received anatoxin-a during week 1. In
fact, group W V A didn’t seem to be affected by anatoxin-a injections at all.
One concern with these percent control values is that they do not support our
derived ED50. The two groups that received anatoxin-a during week 1 (AAAA and
A W A ) both show only a 32% decrease from baseline responding, in VRrsp, following
their first anatoxin-a injections, and the group that received anatoxin-a for the first time
during week 4 (W V A ) showed only a 10% decrease. These values are too far from 50%
to be considered an accurate ED50 value and thus we must conclude that our derived dose
of 92 pg/kg is too low. This comparison is only made in the VRrsp component because
that is the only dependent measure we used to calculate the derived ED50 from the Phase I
data.

Phase III
During phase III, vehicle injections were given before each weekly test session
and anatoxin-a was given after each weekly test session during the first 3 weeks. In week
4, anatoxin-a was administered for the first time before the weekly test session. The only
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anatoxin-a dose (92 pg/kg) used during phase II was the derived ED50 value based on the
results from phase I.
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Figure 6: VR and VI response and reinforcement rates following Phase III vehicle
(saline) or anatoxin-a (92 pg/kg) injections. Baseline values were determined
by averaging data from the day before injections for all rats. Each symbol
represents mean + SEM o f eight rats.
Figure 3 shows VR and VI response rates and reinforcement rates following
Phase III saline and anatoxin-a injections. Baseline values (day before each injection
day) are represented by the circles and Phase III test data are represented by the inverted
triangles. During the first 3 weeks, when vehicle was given before the session, and
anatoxin-a after the session, both response and reinforcement rates were very similar
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indicating that the vehicle injection itself did not affect performance. In week 4, when
anatoxin-a was given before the session, there was only a very small decrease (3% for
VRrsp, 3% for VRmf, 9% for VIrsp and 28% for VImf) in performance levels relative to
week 3, when anatoxin-a was not administered before the session. There was only a very
small change in VI rates from week 3, when vehicle was given before sessions, and the
4th week, when nicotine was given before the session, so any tolerance that occurred was
not purely pharmacological (i.e., due to drug exposure per se). Moreover, this change
was not statistically significant (Pr>F = 0.7769 for VRrsp, 0.8172 for VRmf, 0.3366 for
VIrsp and 0.1291 for V Im f) so the tolerance was not solely behavioral. However, it does
appear in phase III, as with phase II, that our derived ED50 value for anatoxin-a was too
low.

Discussion
Weekly administration of (+)anatoxin-a (50, 75, 100, 150, and 200 pg/kg)
produced behavioral tolerance over a period o f four weeks during Phase I. Initial
(+)anatoxin-a administrations (Week 1) decreased response rates and reinforcement rates
in generally a dose-dependent fashion under both the VR and VI components o f the
multiple schedule. Each subsequent weekly (+)anatoxin-a administration resulted in
slightly higher response and reinforcement rates, indicating tolerance. Additionally, the
two highest does (150 and 200 pg/kg) nearly suppressed all behavior during the first
week, but behavior emerged in the later weeks indicating that tolerance will develop to
(+)anatoxin-a even at doses high enough to nearly eliminate behavior after initial
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exposure. No prior studies have examined tolerance to anatoxin-a, but the results from
the initial administration are similar to findings reported by Stolerman et al. (1992), who
found that anatoxin-a decreased activity in dose-dependent fashion.
During the second phase, when (+)anatoxin-a administrations with the derived
ED50 value (92 pg/kg) were separated by a 3-week period, tolerance did not develop.
Results showed that there was not a significant change in response rates for either the VR
or VI components over the 4-week period. One possible explanation for this
phenomenon is that our derived ED50 value simply w asn’t high enough. There were also
puzzling results with the group that was a replication o f the conditions in Phase I. These
results did not resemble the results in Phase I. Initial administration did produce a
decrease in behavior, and during the second week response rates were greater than the
first. However, during the third week there was an unexplainable sharp decrease in rates
for all components o f the multiple schedule. Given these puzzling findings, the results
of Phase II should be replicated before strong conclusions are drawn concerning the
effects o f administering anatoxin-a less frequently than once a week.
The results o f Phase III do not clarify whether behavioral or pharmacological
tolerance develops to anatoxin-a. The only real effect o f (+)anatoxin-a administration
occurred in the V Im f component, where there was a slight decrease in reinforcement rate.
These results suggest that the derived ED50 value was too low. Phase III needs to be
replicated, using a higher dose o f anatoxin-a.
The present results do clearly indicate that tolerance will develop with weekly
(+)anatoxin-a administration. They do not, however, indicate whether tolerance will
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develop with less-frequent anatoxin-a injections, or whether the tolerance that develops is
pharmacological, behavioral, or a combination of the two. The derived ED50 seems to
have been an ineffective dose, and therefore a higher dose may have produced different
results. Only one published study has examined the behavioral effects o f (+)anatoxin-a
(Stolerman et al., 1992), and further studies, including replications o f the conditions of
Phase II and Phase III with higher doses, are needed to clarify how tolerance develops to
this compound. Research should also explore whether racemic anatoxin-a produces
results similar to those o f the (+) isomer.
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CHAPTER IV
GENERAL DISCUSSION
Weekly administration o f both nicotine and (+)anatoxin-a produced behavioral
tolerance over the course o f four weeks. The two highest doses o f (+)anatoxin-a nearly
suppressed all behavior after the first administration, but then behavior emerged during
subsequent treatments, indicating tolerance could develop even to relatively high doses.
It remains to be determined whether tolerance will develop to similar severely disruptive
nicotine doses, which were not examined in the present study.
With both nicotine and anatoxin-a, a similar degree o f tolerance was observed
under the VI and VR schedules, even though the degree o f initial reinforcement loss
(relative to baseline levels) was greater under the latter schedule. Thus, the present
findings indicate that relative reinforcement loss did not modulate the development of
tolerance to either compound. Some degree o f initial reinforcement loss did, however,
occur under both schedules, thus the present findings are consistent with the
reinforcement-loss hypothesis as initially proposed by Schuster et al. (1966).
At the completion o f Phase I it appeared as though tolerance developed similarly
to (-t-)anatoxin-a and nicotine. This did not appear to be the case in Phase II. When
administrations were separated by a 3-week period, some tolerance developed to nicotine,
but not to (-t-)anatoxin-a. However, it appears that the derived ED50 for (+)anatoxin-a
used in Phase II was too low, and therefore comparisons o f the effects o f nicotine and
anatoxin-a based on these data are suspect. Further research should be conducted to
52
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assess whether tolerance develops to anatoxin-a when it is administered less frequently
than once a week.
In general, prior studies have suggested that there are similarities between
nicotine and (+)anatoxin-a with respect to their neurochemical actions (e.g., MacCallan et
al., 1988; Thomas et al., 1993; Wonnacott et al., 1991) and the current results suggest
that there also are similarities in the behavioral effects o f the two compounds with both
acute and weekly administrations. Further testing is needed, however, to fully ascertain
the extent of these similarities.
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